Rifaximin
Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
1. A pharmaceutical composition comprising rifaximin in an amorphous form characterized by the XRPD pattern shown in FIG. 1 in combination with a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a caplet, a lozenge, dispersible granules, a dry powder syrup, a ready-to-use suspension, a parental dosage form, an inhalation formulations, or a transdermal formulation.
3. A method of treating bowel related disorders comprising administering a therapeutically effective amount of rifaximin as a medicament to a patient in need thereof, wherein the rifaximin is in an amorphous form characterized by the XRPD pattern shown in FIG. 1 .
4. The method according to claim 3 , wherein the medicament is for treating irritable bowel syndrome.
5. The method according to claim 3 , wherein the medicament is for treating diarrhea.
6. The method according to claim 3 , wherein the medicament is for treating traveler's diarrhea.
7. The method according to claim 3 , wherein the medicament is for treating microbe associated diarrhea.
8. The method according to claim 3 , wherein the medicament is for treating Crohn's disease.
9. The method according to claim 3 , wherein the medicament is for treating chronic pancreatitis.
10. The method according to claim 3 , wherein the medicament is for treating pancreatic insufficiency.
11. The method according to claim 3 , wherein the medicament is for treating colitis.